Azevedo C, Andersen JT, Traverso G, Sarmento B (2021)
The potential of porcine ex vivo platform for intestinal permeability screening of FcRn-targeted drugs
Eur J Pharm Biopharm, 162, 99-104
DOI 10.1016/j.ejpb.2021.03.009, PubMed 33771621

Mester S, Evers M, Meyer S, Nilsen J, Greiff V, Sandlie I, Leusen J, Andersen JT (2021)
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
MAbs, 13 (1), 1893888
DOI 10.1080/19420862.2021.1893888, PubMed 33691596

Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, Dagnæs-Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA (2021)
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity
Commun Biol, 4 (1), 310
DOI 10.1038/s42003-021-01790-2, PubMed 33686177